In red positive intraday performance, we signal: – we sold OREX (NASDAQ) at 6,45 with 20% gain – TRGT (NASDAQ) surpassing 8 usd, up 6% to 8,4 usd – CYTR (NASDAQ) up 8% – INCY (NASDAQ) up 4,5% to 4 usd – GTXI (NASDAQ) up 5,5% – NGSX (NASDAQ) up 5% well above 7 usd – OCLS (NASDAQ) up 7,5% – We have added IDIX (NASDAQ) with strong consensus and SNTS(nasdaq) with a FDA decison for its product by december, both for LT – DDSS (NASDAQ): Labopharm receives complete response letter from the U.S. FDA for novel antidepressant, no safety or efficay issues, manifacturig issues, we are still hold ing the stock in spite of possible today sell off TICKER BUY AREA QUOTE NOW POSITION DRIVER IDIX (NASDAQ) USD 4,44 5 LONG TERM STRONG CONSENSUS SNTS (NASDAQ) USD 2,81 3 LONG TERM FDA REVIEW Zegerid BY DECEMBER BFRM (NASDAQ) USD 2,85 2 LONG TERM OVERSOLD CONDITIONS OCLS (NASDAQ) USD 2,85 2,75 LONG TERM MORE UPSIDE TRGT (NASDAQ) USD 5,5 8,4 STRONG BUY Targacept’s TC-5214 results OREX (NASDAQ) USD 5,35 6,45 SOLD(+20%) FOLD (NASADQ) USD 10 10,4 LONG TERM PLICERA, AMIGAL STRONG CONSENSUS SOMX (NASDAQ) USD 1,10 1,38 SOLD (+25%) DDSS (NASDAQ) USD 2,65 2 SHORT TERM TRAZODONE FDA PDUFA 7/18/09 XNPT (NASDAQ) USD 21,85 20,5 LONG TERM XP19986 POSITIVE TRIAL 6/30/09 VNDA (NASDAQ) 12,1 12,95 REBUYING FANAT APPROVED 5/6/09 CYTR (NASDAQ) USD 1,02 1,2 LONG TERM STRONG CONSENSUS JAZZ (NASDAQ) USD 4,95 4 LONG TERM STRONG CONSENSUS PARD (NASDAQ) USD 5 5,9 PROFIT TAKING(+18%) PARD (NASDAQ) USD 6,6 rebought 7/2 7,1 LONG TERM STRONG CONSENSUS INCY (NASDAQ) USD 3,5 4 LONG TERM STRONG CONSENSUS ISTA (NASDAQ) USD 4,1 4,45 LONG TERM BEPREVE FDA PDUFA 9/12/09 JAV (AMEX) USD 1,3 1,6 LONG TERM STRONG CONSENSUS SLXP (NASDAQ) USD 9,9 11,15 LONG TERM STRONG CONSENSUS FDA PDUFA 9/9/09 MAPP (NASDAQ) USD 11,3 10 REBUYING LONG TERM STRONG CONSENSUS ARYX (NASDAQ) USD 4,5 SOLD 2,5 (-45%) ARRY (NASDAQ) USD 3,1 3,2 LONG TERM CLINICAL TRIAL 7/8/09 GTXI (NASDAQ) USD 9,5 8,7 LONG TERM FDA PDUFA 10/30/09 UTHR (NASDAQ) USD 84 85 LONG TERM FDA PDUFA 7/30/09 NGSX (NASDAQ) USD 6,4 7,4 LONG TERM FDA PDUFA 8/16/09 VICL (NASDAQ) USD 3 2,7 LONG TERM SWINE FLU STAA (NASDAQ) USD 3,3 2,3 LONG TERM FDA CLEARENCE FOR Epiphany(TM) ALTH (NASDAQ) 7,9 7,6 LONG TERM FDA PDUFA 9/24/09 AMAG (NASDAQ) 52,8 50,8 LONG TERM FDA APPROVES FERAHEME 6/30/09 XOMA (NASDAQ) 1,2 0,78 LONG TERM OVERSOLD HEB (AMEX) 3,3(5%OF CAPITAL) 2,25 SOLD(-35%) HEB (AMEX) was rebought after 100% gain (see old posts) MRNA (NASDAQ) 3,3 1,5 LONG TERM OVERSOLD RIGL (NASDAQ) USD 10 14,4 LONG TERM STRONG CONSENSUS MITI (NASDAQ) USD 6 5 LONG TERM OVERSOLD MNKD (NASDAQ) USD 8,3 7,95 SOLD(-4%) SVNT (NASDAQ) USD 7,10 13 SOLD(+90%) NPSP (NASDAQ) 3,1 USD 4,75 SOLD(+50%) SCLN (NASDAQ) 2,25 USD 2,7 SOLD (+20%) LONG TERM ZADAXIN SALES MAPP (NASDAQ) 8 USD (posts from 5/26) PROFIT TAKED(+45%) LEVADEX VNDA (NASDAQ) 8 USD (see old post 5/8) PROFIT TAKED(+80%) FANAT CLDA (NASDAQ) 15,7 USD 9,5 LONG TERM OVERSOLD CTIC (NASDAQ) 2,10 USD 1,39 SOLD (-35%) ANPI (NASDAQ) 2 USD 1,39 SOLD(-30%) MEDX (NASDAQ) 7,5 USD 8,7 PROFIT TAKING(+20%) LTERM RECENT PRODUCTS RESULTS MNTA (NASDAQ) 8,9 USD 11,4 LONG TERM STRONG CONSENSUS ACAD (NASDAQ) 2,6 USD 2,35 LONG TERM CLINICAL DATA 3 Q
Per approfondire consulta articolo originale:
trading-news biopharma stock list update: orex, trgt
Articoli correlati:
Nessun commento per ora.
Segui il feed dei commenti a questo post
Scrivi un commento
Nessun Commento